How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/treatment-refractory-type-2-diabetes-mellitus.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Treatment Refractory Type 2 Diabetes Mellitus — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment Refractory Type 2 Diabetes Mellitus (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Treatment Refractory Type 2 Diabetes Mellitus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Avandia	ROSIGLITAZONE	Woodward	Peroxisome Proliferator Receptor gamma Agonist	CDGSH iron-sulfur domain-containing protein 1	1999-01-01
Glucophage	metformin	Generic (originally Merck Serono/Lipha)	Dipeptidyl Peptidase 4 Inhibitor [EPC]	5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2	1995-03-03
Amaryl	GLIMEPIRIDE	Sanofi	Sulfonylurea [EPC]	Sulfonylurea receptor 1, Kir6.2	1995-01-01
Glucophage	Glucophage	Dr. Reddy's Laboratories Limited		5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Dr. Reddy's Laboratories Limited · 1 drug in Treatment Refractory Type 2 Diabetes Mellitus
Generic (originally Merck Serono/Lipha) · 1 drug in Treatment Refractory Type 2 Diabetes Mellitus
Sanofi · 1 drug in Treatment Refractory Type 2 Diabetes Mellitus
Woodward · 1 drug in Treatment Refractory Type 2 Diabetes Mellitus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Treatment Refractory Type 2 Diabetes Mellitus:

Cite this brief

Drug Landscape (2026). Treatment Refractory Type 2 Diabetes Mellitus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-refractory-type-2-diabetes-mellitus. Accessed 2026-06-10.

Treatment Refractory Type 2 Diabetes Mellitus full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing